Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study.

Antonio LeidiFlora KoeglerRoxane DumontRichard DubosMaría-Eugenia ZaballaGiovanni PiumattiMatteo CoenAmandine BernerPauline Darbellay FarhoumandPauline VetterNicolas VuilleumierLaurent KaiserDelphine CourvoisierAndrew S AzmanIdris GuessousSilvia Stringhininull null

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

Seroconversion after SARS-CoV-2 infection confers protection against reinfection lasting at least 8 months. These findings could help global health authorities establishing priority for vaccine allocation.

Keyphrases

global health
sars cov
respiratory syndrome coronavirus
public health
coronavirus disease